AU2002338666B2 - Multiplication of viruses in a cell culture - Google Patents
Multiplication of viruses in a cell culture Download PDFInfo
- Publication number
- AU2002338666B2 AU2002338666B2 AU2002338666A AU2002338666A AU2002338666B2 AU 2002338666 B2 AU2002338666 B2 AU 2002338666B2 AU 2002338666 A AU2002338666 A AU 2002338666A AU 2002338666 A AU2002338666 A AU 2002338666A AU 2002338666 B2 AU2002338666 B2 AU 2002338666B2
- Authority
- AU
- Australia
- Prior art keywords
- virus
- cells
- viruses
- medium
- multiplication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 256
- 238000004113 cell culture Methods 0.000 title claims abstract description 61
- 208000015181 infectious disease Diseases 0.000 claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 83
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 5
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 5
- 239000002609 medium Substances 0.000 claims description 129
- 238000004114 suspension culture Methods 0.000 claims description 32
- 239000012737 fresh medium Substances 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 17
- 239000001963 growth medium Substances 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 12
- 239000012092 media component Substances 0.000 claims description 10
- 239000012228 culture supernatant Substances 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 241000709721 Hepatovirus A Species 0.000 claims description 8
- 241000711798 Rabies lyssavirus Species 0.000 claims description 7
- 230000010412 perfusion Effects 0.000 claims description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000005199 ultracentrifugation Methods 0.000 claims description 5
- 241000710831 Flavivirus Species 0.000 claims description 4
- 241000702244 Orthoreovirus Species 0.000 claims description 4
- 241000711902 Pneumovirus Species 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 241000702263 Reovirus sp. Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 241000712891 Arenavirus Species 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000701157 Canine mastadenovirus A Species 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- -1 auxiliary Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 241000209094 Oryza Species 0.000 claims 2
- 235000007164 Oryza sativa Nutrition 0.000 claims 2
- 235000009566 rice Nutrition 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 191
- 235000018102 proteins Nutrition 0.000 description 40
- 238000003306 harvesting Methods 0.000 description 30
- 238000012258 culturing Methods 0.000 description 26
- 238000010790 dilution Methods 0.000 description 25
- 239000012895 dilution Substances 0.000 description 25
- 238000007792 addition Methods 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
- 230000001464 adherent effect Effects 0.000 description 16
- 239000012894 fetal calf serum Substances 0.000 description 16
- 239000000654 additive Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 8
- 238000004115 adherent culture Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- 239000007640 basal medium Substances 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000004017 serum-free culture medium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960000380 propiolactone Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011177 media preparation Methods 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102100026044 Biotinidase Human genes 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000709711 Coxsackievirus B5 Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000873785 Homo sapiens mRNA-decapping enzyme 1A Proteins 0.000 description 1
- 241000709573 Human hepatitis A virus Hu/Australia/HM175/1976 Species 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000006253 efflorescence Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 102100035856 mRNA-decapping enzyme 1A Human genes 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 244000045561 useful plants Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12051—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10144903A DE10144903A1 (de) | 2001-09-12 | 2001-09-12 | Vermehrung von Viren in Zellkultur |
| DE10144903.8 | 2001-09-12 | ||
| PCT/EP2002/010207 WO2003023025A1 (de) | 2001-09-12 | 2002-09-11 | Vermehrung von viren in zellkultur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002338666A1 AU2002338666A1 (en) | 2003-06-19 |
| AU2002338666B2 true AU2002338666B2 (en) | 2008-11-20 |
Family
ID=7698761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002338666A Ceased AU2002338666B2 (en) | 2001-09-12 | 2002-09-11 | Multiplication of viruses in a cell culture |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050118698A1 (https=) |
| EP (1) | EP1427817B1 (https=) |
| JP (2) | JP2005502357A (https=) |
| KR (1) | KR100968141B1 (https=) |
| AT (1) | ATE466932T1 (https=) |
| AU (1) | AU2002338666B2 (https=) |
| BR (1) | BR0212469A (https=) |
| CA (1) | CA2456561A1 (https=) |
| CY (1) | CY1110716T1 (https=) |
| DE (2) | DE10144903A1 (https=) |
| DK (1) | DK1427817T3 (https=) |
| ES (1) | ES2345606T3 (https=) |
| NZ (1) | NZ532203A (https=) |
| PT (1) | PT1427817E (https=) |
| SI (1) | SI1427817T1 (https=) |
| WO (1) | WO2003023025A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007537760A (ja) * | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
| ATE489965T1 (de) | 2004-09-09 | 2010-12-15 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| ES2525518T3 (es) | 2005-11-01 | 2014-12-26 | Novartis Vaccines And Diagnostics Gmbh | Vacunas virales derivadas de células con niveles reducidos de ADN celular residual |
| JP2009514844A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
| CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
| CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP4585610A3 (en) * | 2006-09-11 | 2025-09-24 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| EP2615167A1 (en) | 2006-09-15 | 2013-07-17 | MedImmune, LLC | Method for eliminating DNA contaminants from viral preparations |
| KR20100045437A (ko) | 2007-06-27 | 2010-05-03 | 노파르티스 아게 | 첨가물이 적은 인플루엔자 백신 |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| US8785173B2 (en) | 2008-09-24 | 2014-07-22 | Medimmune, Llc | Methods for purification of viruses |
| EP2344634A4 (en) | 2008-09-24 | 2012-08-29 | Medimmune Llc | METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES |
| CA2741961A1 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
| USH2283H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
| CA2778332A1 (en) * | 2009-10-20 | 2011-04-28 | Novartis Ag | Improved reverse genetics methods for virus rescue |
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| US9426989B2 (en) | 2010-05-06 | 2016-08-30 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
| CN103025350A (zh) | 2010-05-21 | 2013-04-03 | 诺华有限公司 | 流感病毒的重配方法 |
| WO2011151723A2 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| WO2012023044A1 (en) | 2010-08-20 | 2012-02-23 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
| SG192821A1 (en) * | 2011-02-17 | 2013-09-30 | Boehringer Ingelheim Vetmed | Commercial scale process for production of prrsv |
| CA2829774C (en) | 2011-03-14 | 2019-09-24 | National Research Council Of Canada | Method of viral production in cells |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| EP2822585B1 (en) | 2012-03-06 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Improved vaccination against influenza |
| WO2014031480A1 (en) * | 2012-08-24 | 2014-02-27 | Xcellerex, Inc. | Virus purification and formulation process |
| KR101370512B1 (ko) * | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
| US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| KR102790570B1 (ko) | 2015-07-07 | 2025-04-04 | 세퀴러스 유케이 리미티드 | 인플루엔자 효능 검정 |
| CN105561317B (zh) * | 2015-12-22 | 2018-03-20 | 肇庆大华农生物药品有限公司 | 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法 |
| CN108239619A (zh) * | 2016-12-23 | 2018-07-03 | 甘肃健顺生物科技有限公司 | 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术 |
| CN108570444A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | St细胞驯化悬浮方法和二阶病毒生产工艺 |
| CN108570445A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | Pk15细胞驯化悬浮方法和二阶病毒生产工艺 |
| CN108570454A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | Mdbk驯化悬浮方法和二阶病毒生产工艺 |
| EP4061930A1 (en) | 2019-11-18 | 2022-09-28 | Seqirus Pty Ltd | Method for producing reassortant influenza viruses |
| KR102444684B1 (ko) * | 2020-04-29 | 2022-09-16 | 에스케이바이오사이언스(주) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002548A2 (en) * | 1999-07-01 | 2001-01-11 | Glaxo Group Limited | Methods for the propagation of lytic organisms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| KR19990072201A (ko) * | 1996-10-18 | 1999-09-27 | 무타이 마사히꼬 | 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법 |
| KR100797547B1 (ko) * | 2000-03-03 | 2008-01-24 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
-
2001
- 2001-09-12 DE DE10144903A patent/DE10144903A1/de not_active Ceased
-
2002
- 2002-09-11 JP JP2003527090A patent/JP2005502357A/ja active Pending
- 2002-09-11 CA CA002456561A patent/CA2456561A1/en not_active Abandoned
- 2002-09-11 WO PCT/EP2002/010207 patent/WO2003023025A1/de not_active Ceased
- 2002-09-11 ES ES02777068T patent/ES2345606T3/es not_active Expired - Lifetime
- 2002-09-11 KR KR1020047003711A patent/KR100968141B1/ko not_active Expired - Lifetime
- 2002-09-11 AT AT02777068T patent/ATE466932T1/de active
- 2002-09-11 EP EP02777068A patent/EP1427817B1/de not_active Expired - Lifetime
- 2002-09-11 DE DE50214416T patent/DE50214416D1/de not_active Expired - Lifetime
- 2002-09-11 AU AU2002338666A patent/AU2002338666B2/en not_active Ceased
- 2002-09-11 PT PT02777068T patent/PT1427817E/pt unknown
- 2002-09-11 DK DK02777068.4T patent/DK1427817T3/da active
- 2002-09-11 NZ NZ532203A patent/NZ532203A/en not_active IP Right Cessation
- 2002-09-11 US US10/487,709 patent/US20050118698A1/en not_active Abandoned
- 2002-09-11 SI SI200230909T patent/SI1427817T1/sl unknown
- 2002-09-11 BR BR0212469-6A patent/BR0212469A/pt not_active IP Right Cessation
-
2010
- 2010-06-25 JP JP2010145663A patent/JP2010246559A/ja active Pending
- 2010-07-30 CY CY20101100718T patent/CY1110716T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002548A2 (en) * | 1999-07-01 | 2001-01-11 | Glaxo Group Limited | Methods for the propagation of lytic organisms |
Non-Patent Citations (3)
| Title |
|---|
| Journal of Virology, 64(12): 6040-44, Dec 1990 * |
| Journal of Virology, 69(9): 5535-43, Sept. 1995 * |
| Virology, 194: 200-209, 1993 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1062029A1 (zh) | 2004-10-15 |
| SI1427817T1 (sl) | 2010-08-31 |
| DK1427817T3 (da) | 2010-08-23 |
| CY1110716T1 (el) | 2015-06-10 |
| DE10144903A1 (de) | 2003-03-27 |
| ES2345606T3 (es) | 2010-09-28 |
| BR0212469A (pt) | 2004-08-24 |
| ATE466932T1 (de) | 2010-05-15 |
| PT1427817E (pt) | 2010-08-10 |
| US20050118698A1 (en) | 2005-06-02 |
| JP2005502357A (ja) | 2005-01-27 |
| KR100968141B1 (ko) | 2010-07-06 |
| CA2456561A1 (en) | 2003-03-20 |
| EP1427817B1 (de) | 2010-05-05 |
| WO2003023025A1 (de) | 2003-03-20 |
| DE50214416D1 (de) | 2010-06-17 |
| KR20050027164A (ko) | 2005-03-17 |
| NZ532203A (en) | 2005-04-29 |
| EP1427817A1 (de) | 2004-06-16 |
| JP2010246559A (ja) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002338666B2 (en) | Multiplication of viruses in a cell culture | |
| US10329536B2 (en) | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an MDCK cell suspension culture | |
| JP5264843B2 (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
| JP4243349B2 (ja) | インフルエンザウイルスの複製のための動物細胞および方法 | |
| HK1062029B (en) | Multiplication of viruses in a cell culture | |
| HK1149046A (en) | Method for manufacturing an active component of a medicine or diagnosis agent in mdcj cell suspension culture | |
| HK1062030B (en) | Methods for the industrial production of vaccines | |
| Arifin et al. | Research Article Production of Newcastle Disease Virus by Vero Cells Grown on Cytodex 1 Microcarriers in a 2-Litre Stirred Tank Bioreactor | |
| HK1019233B (en) | Animal cells and processes for the replication of influenza viruses | |
| HK1152546A (en) | Animal cells and processes for the replication of influenza viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application | ||
| NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 11 SEP 2007 TO 11 NOV 2008 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED . |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 11 NOV 2008. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| TH | Corrigenda |
Free format text: IN VOL 23, NO 15, PAGE(S) 7650 UNDER THE HEADING CHANGE OF NAMES(S) OF APPLICANT(S), SECTION 104 - 2002 UNDER THE NAME NOARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG, APPLICATION NO. 2002338666, UNDER INID (71), CORRECT THE NAME TO READ NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |